Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer.

by Manish A Shah, Zev A Wainberg, Daniel V T Catenacci, Howard S Hochster, James Ford, Pamela Kunz, Fa-Chyi Lee, Howard Kallender, Fabiola Cecchi, Daniel C Rabe, Harold Keer, Anne-Marie Martin, Yuan Liu, Robert Gagnon, Peter Bonate, Li Liu, Tona Gilmer, Donald P Bottaro
Published 2013-01-01

Rethinking the Role of Radiation Therapy in the Treatment of Unresectable Hepatocellular Carcinoma: A Data Driven Treatment Algorithm for Optimizing Outcomes

by Mutlay Sayan, Nikhil Yegya-Raman, Stephanie H. Greco, Bin Gui, Andrew Zhang, Anupama Chundury, Miral S. Grandhi, Howard S. Hochster, Timothy J. Kennedy, Russell C. Langan, Usha Malhotra, Vinod K. Rustgi, Mihir M. Shah, Kristen R. Spencer, Darren R. Carpizo, John L. Nosher, Salma K. Jabbour
Published 2019-06-01